Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-dose Priorix versus M-M-RVAXPRO in healthy subjects aged 7 years and older
2011-003672-36Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2014
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in measles, mumps and rubella comparing Priorix second dose with M-M-RVAXPRO second dose (2 arms). Primary endpoint: Immunogenicity in terms of antibody response. Started Aug 2014; status: completed.
02
Drugs
measles, mumps and rubella vaccine (live)M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2011-003672-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003672-36.